Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480414 | 0.87 | BRD4 (0.44) | BRD4CREBBPPAX8PTGER2PTGER3 | |
| SCHEMBL9891744 | 0.85 | SMN1; SMN2 (0.38) | PTGER2PTGER3PTGDRCNR2 | |
| SCHEMBL9106214 | 0.85 | HDAC6 (0.39) | BRD4CREBBPPAX8PTGER2PTGER3 | |
| SCHEMBL2572517 | 0.85 | HDAC6 (0.39) | BRD4CREBBPPAX8PTGER2PTGER3 | |
| SCHEMBL9893043 | 0.84 | PTGER2 (0.43) | BRD4CREBBPPAX8PTGER2PTGER3 | |
| SCHEMBL9891745 | 0.75 | LMNA (0.36) | PTGER2PTGER3CNR2KMT2AMEN1 | |
| SCHEMBL8018111 | 0.74 | PAX8 (0.55) | BRD4CREBBPPAX8MT-CO2KMT2A | |
| SCHEMBL9102239 | 0.73 | CNR2 (0.70) | CNR2 | |
| SCHEMBL9102252 | 0.73 | CNR2 (0.70) | CNR2 | |
| SCHEMBL9891746 | 0.72 | CNR2 (0.45) | PTGER2PTGER3CNR2TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | BRD4 143/4885CREBBP 245/4885PAX8 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.